Prognostic value of early treatment response in children with acute lymphoblastic leukemia: A single institution experience in Shanghai, China

Chinese Journal of Contemporary Pediatrics

Volumn 11, Issue 1, 2009, Pages 5-9

  Tie, Li Jun ^a,b   Gu, Long Jun ^a   Song, De Lian ^a   Jiang, Li Min ^a   Xue, Hui Liang ^a   Tang, Jing Yan ^a   Dong, Lu ^a   Pan, Ci ^a   Chen, Jing ^a   Ye, Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Child; Leukemia; Lymphoblast count; Lymphoblastic, acute; Minimal residual disease; Prognostic factor

Indexed keywords

ASPARAGINE; DAUNORUBICIN; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHINA; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; INFANT; LEUKEMIA REMISSION; LEUKEMOGENESIS; LYMPHOBLAST; LYMPHOCYTE COUNT; LYMPHOCYTE STRUCTURE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PROGNOSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 58649109608     PISSN: 10088830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia [J]. N Engl Med, 2006, 354(2): 166-178.
2. Pui CH, Robison L, TomasLook A. Acute lymphoblastic leukemia [J]. Lancet, 2008, 371(9617):1030-1043.
3. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995[J]. Leukemia, 2000, 4(12): 2223-2233.
4. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995[J]. Leukemia, 2000, 14(12):2205-2222.
5. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90[J]. Blood, 2000, 95(11): 3310-3322.
6. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia[J]. Blood, 1995, 86(4):1292-1295.
7. Pui CH, Compana D. New definition of remission in childhood acute lymphoblastic leukemia[J]. Leukemia, 2000, 14(5):783-785.
8. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia [J]. Lancet, 1998, 352(9142):1731-1738.
9. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia [J]. Blood, 2000, 96(8): 2691-2696.
10. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia[J]. Leukemia, 2008, 22(4):771-782.
11. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study[J]. Blood, 2008, 111(12):5477-5485.
12. Gu LJ, Li J, Xue HL, Tang JY, Chen J, Zhao HJ, et al. Analysis of therapeutic effectiveness in 158 childhood acute lymphoblastic leukemia patients treated with ALL-XH-99 protocol (in Chinese) [J]. Chin J Hematol, 2004, 25(1):14.
13. Campana D. Status of minimal residual disease testing in childhood haematological malignancies [J]. Br J Haematol, 2008, 43(4): 481-489.
14. Sandlund JT, Harrison PL, Rivera G, Behm FG, Head D, Boyett J, et al. Persistence of lymphoblasts in bone marrow on day 15 and day 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia [J]. Blood, 2002, 100(1): 43-47.